Time-varying serum uric acid predicts new-onset atrial fibrillation in treated hypertensive patients. The LIFE Study

Aim: The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study showed less new-onset atrial fibrillation (AF) in hypertensive patients receiving losartan- vs. atenolol-based treatment. Because losartan reduces serum uric acid (SUA) levels, the aim of the present study was to inve...

Descrición completa

Detalles Bibliográficos

Principais autores:	Eran S. Zacks, Ildri M. Stokke, Kristian Wachtell, Darcy A. Hille, Aud Høieggen, Sverre E. Kjeldsen, Stevo Julius, Eva Gerdts, Peter M. Okin, Richard B. Devereux
Formato:	Artigo
Idioma:	Inglês
Publicado:	Open Exploration Publishing Inc. 2022-03-01
Series:	Exploration of Medicine
Assuntos:	atrial fibrillation blood pressure hypertension left ventricular hypertrophy serum uric acid
Acceso en liña:	https://www.explorationpub.com/Journals/em/Article/100179
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!